Singular Genomics to Present at the UBS Genomics 2.0 and MedTech Innovations Summit

SAN DIEGO, July 28, 2022 (GLOBE NEWSWIRE) — Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today announced plans to present at the UBS Genomics 2.0 and MedTech Innovations Summit in Laguna Beach, California.

Singular Genomics’ management is scheduled to participate in a fireside chat Thursday, August 11, 2022, at 1:00 p.m. Pacific Time / 4:00 p.m. Eastern Time. Investors and other interested parties are invited to listen to a live and recorded webcast of the presentation at investor.singulargenomics.com, in the Presentations & Events section.

About Singular Genomics Systems, Inc.
Singular Genomics is a life science technology company that develops next-generation sequencing and multiomics technologies. The commercially available G4 Sequencing Platform is a powerful, highly versatile benchtop genomic sequencer designed to produce fast and accurate results. In development, the PX system leverages Singular’s proprietary sequencing technology, applying it as an in-situ readout to look at RNA and proteins in single cells and tissue. With these products, Singular Genomics’ mission is to empower researchers and clinicians to advance science and medicine.

Investor Contact
Matt Clawson
949-370-8500
[email protected]

Media Contact
Dan Budwick, 1AB
973-271-6085
[email protected]